The vaccine is a proprietary adenovector delivery system capable of generating strong immune responses while avoiding vector-specific immunity.
Clinical data from a Phase 1 malaria vaccine trial conducted by NMRC and the Walter Reed Army Institute of Research, using GenVec adenovector technology coupled with DNA plasmid priming, indicated the vaccine "was safe and well-tolerated with minimal local or systemic reactions and no serious vaccine-related adverse reactions," GenVec said.
"We appreciate the U.S. military's continued commitment to the worldwide problem of malaria and its support of malaria vaccine development," said Joseph Bruder, director of research and head of GenVec's malaria program. "Work under this agreement will build upon the encouraging clinical results previously demonstrated."
The contract for supply of the vaccine for further clinical testing is worth about $3.5 million.
Celebrity Breakups and divorces of 2014 [PHOTOS]